Edwards Lifesciences has obtained a CE Mark for the MITRIS RESILIA valve, a tissue valve replacement designed for the mitral position of the heart.

The valve is produced using bovine pericardial tissue technology to minimise calcium accumulation.

The saddle-shaped sewing cuff of the valve mimics the asymmetrical form of the native mitral valve.

MITRIS RESILIA is a low-profile valve that deploys the Edwards PERIMOUNT valve design and incorporates a nitinol wire form that enables it to fold inward at the time of implantation.

The valve can be seen under fluoroscopy, which enables potential transcatheter interventions for patients in the future.

New findings from the COMMENCE aortic trial showed promising outcomes for the RESILIA tissue, including a 99.3% freedom from structural valve deterioration rate, stable gradients and 97.2% freedom from reoperation over seven years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The RESILIA anti-calcification technology also facilitates the storage of devices under dry packaging conditions.

Edwards Surgical Europe senior vice-president John Barry said: “Edwards Lifesciences is committed to addressing the needs of patients with structural heart disease.

“Our RESILIA tissue technology is designed for enhanced durability, supporting improved quality of life for patients and relieving the burden on healthcare systems.”

Last year, the company received approval from the US Food and Drug Administration for the MITRIS RESILIA valve.

In September this year, the Ohio State University Wexner Medical Center in the US randomised the world’s first patient in a clinical trial to assess the effectiveness of Edwards’ device aimed at relieving symptoms of heart failure.